Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1951 2
1956 1
1958 1
1959 2
1961 4
1962 4
1963 7
1964 14
1965 9
1966 17
1967 14
1968 14
1969 27
1970 16
1971 12
1972 13
1973 19
1974 24
1975 23
1976 17
1977 23
1978 28
1979 21
1980 19
1981 35
1982 38
1983 34
1984 39
1985 34
1986 43
1987 51
1988 47
1989 57
1990 56
1991 63
1992 59
1993 56
1994 88
1995 62
1996 74
1997 70
1998 81
1999 89
2000 101
2001 106
2002 99
2003 127
2004 118
2005 119
2006 131
2007 113
2008 119
2009 125
2010 146
2011 155
2012 173
2013 163
2014 151
2015 159
2016 158
2017 194
2018 149
2019 194
2020 216
2021 271
2022 218
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

4,526 results
Results by year
Filters applied: . Clear all
Page 1
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: matsumoto h. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, Matsumoto H, Matsuura H, Matsubara T, Shimizu K, Ogura H, Matsuura Y, Kishimoto T. Kang S, et al. Among authors: matsumoto h. Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22351-22356. doi: 10.1073/pnas.2010229117. Epub 2020 Aug 21. Proc Natl Acad Sci U S A. 2020. PMID: 32826331 Free PMC article.
Second-Generation Antipsychotic Drugs for Children and Adolescents.
Onishi Y, Mikami K, Kimoto K, Watanabe N, Takahashi Y, Akama F, Yamamoto K, Matsumoto H. Onishi Y, et al. Among authors: matsumoto h. J Nippon Med Sch. 2021 Mar 11;88(1):10-16. doi: 10.1272/jnms.JNMS.2021_88-108. Epub 2020 Sep 30. J Nippon Med Sch. 2021. PMID: 32999174 Free article. Review.
Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders.
Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget-Faysse M, Behar-Cohen F, Hartnett ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca PM. Spaide RF, et al. Among authors: matsumoto h. Prog Retin Eye Res. 2022 Jan;86:100973. doi: 10.1016/j.preteyeres.2021.100973. Epub 2021 May 21. Prog Retin Eye Res. 2022. PMID: 34029721 Free article. Review.
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
Saito G, Oya Y, Taniguchi Y, Kawachi H, Daichi F, Matsumoto H, Iwasawa S, Suzuki H, Niitsu T, Miyauchi E, Yokoi T, Yokoyama T, Uenami T, Sakata Y, Arai D, Okada A, Nagata K, Teraoka S, Kokubo M. Saito G, et al. Among authors: matsumoto h. Lung Cancer. 2021 Nov;161:86-93. doi: 10.1016/j.lungcan.2021.08.019. Epub 2021 Sep 5. Lung Cancer. 2021. PMID: 34543942
[PATHOPHYSIOLOGY OF ASTHMA].
Matsumoto H. Matsumoto H. Arerugi. 2022;71(9):1065-1071. doi: 10.15036/arerugi.71.1065. Arerugi. 2022. PMID: 36372415 Japanese. No abstract available.
Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia.
Di Lazzaro V, Bella R, Benussi A, Bologna M, Borroni B, Capone F, Chen KS, Chen R, Chistyakov AV, Classen J, Kiernan MC, Koch G, Lanza G, Lefaucheur JP, Matsumoto H, Nguyen JP, Orth M, Pascual-Leone A, Rektorova I, Simko P, Taylor JP, Tremblay S, Ugawa Y, Dubbioso R, Ranieri F. Di Lazzaro V, et al. Among authors: matsumoto h. Clin Neurophysiol. 2021 Oct;132(10):2568-2607. doi: 10.1016/j.clinph.2021.05.035. Epub 2021 Jul 20. Clin Neurophysiol. 2021. PMID: 34482205 Review.
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Hayakawa Y, Tsuchiya K, Kurosaki M, Yasui Y, Kaneko S, Tanaka Y, Ishido S, Inada K, Kirino S, Yamashita K, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Izumi N. Hayakawa Y, et al. Among authors: matsumoto h. Invest New Drugs. 2022 Apr;40(2):392-402. doi: 10.1007/s10637-021-01185-4. Epub 2021 Sep 29. Invest New Drugs. 2022. PMID: 34586531
4,526 results